124 related articles for article (PubMed ID: 35780816)
41. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
Wolff HB; Alberts L; van der Linden N; Bongers ML; Verstegen NE; Lagerwaard FJ; Hofman FN; Uyl-de Groot CA; Senan S; El Sharouni SY; Kastelijn EA; Schramel FMNH; Coupé VMH
Lung Cancer; 2020 Mar; 141():89-96. PubMed ID: 31982640
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
Khoo T; Gao L
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
[No Abstract] [Full Text] [Related]
43. Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective.
Yip CY; Greystoke A; Abogunrin S; Belleli R; Di Maio D; Rouse P; Jovanoski N
Lung Cancer; 2023 May; 179():107171. PubMed ID: 36947997
[TBL] [Abstract][Full Text] [Related]
44. Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non-Small Cell Lung Cancer in the Irish Healthcare Setting.
Chu RW; Vegas García A; Hickey C; Power DG; Gorry C
Value Health; 2023 Mar; 26(3):402-410. PubMed ID: 36368626
[TBL] [Abstract][Full Text] [Related]
45. Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.
Murray A; Lourenco T; de Verteuil R; Hernandez R; Fraser C; McKinley A; Krukowski Z; Vale L; Grant A
Health Technol Assess; 2006 Nov; 10(45):1-141, iii-iv. PubMed ID: 17083853
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC.
Hussain S; Klugarova J; Klugar M
Lung Cancer; 2022 Aug; 170():11-19. PubMed ID: 35691134
[TBL] [Abstract][Full Text] [Related]
47. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
[TBL] [Abstract][Full Text] [Related]
48. Incremental cost-effectiveness of adult spinal deformity surgery: observed quality-adjusted life years with surgery compared with predicted quality-adjusted life years without surgery.
McCarthy I; O'Brien M; Ames C; Robinson C; Errico T; Polly DW; Hostin R;
Neurosurg Focus; 2014 May; 36(5):E3. PubMed ID: 24785485
[TBL] [Abstract][Full Text] [Related]
49. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (
Nilsson FOL; Gal P; Houisse I; Ivanova JI; Asanin ST
J Med Econ; 2021; 24(1):447-457. PubMed ID: 33754924
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
Shao T; Ren Y; Zhao M; Tang W
Front Public Health; 2022; 10():912921. PubMed ID: 36045725
[TBL] [Abstract][Full Text] [Related]
51. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
Ezeife DA; Kirk V; Chew DS; Nixon NA; Lee R; Le LW; Chan KK; Leighl NB
Lung Cancer; 2018 Nov; 125():1-7. PubMed ID: 30429004
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
Zhou K; Jiang C; Li Q
Lung Cancer; 2019 Oct; 136():98-101. PubMed ID: 31476529
[TBL] [Abstract][Full Text] [Related]
53. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.
Das M; Ogale S; Jovanoski N; Johnson A; Nguyen C; Bhagwakar J; Lee JS
Immunotherapy; 2023 Jun; 15(8):573-581. PubMed ID: 37021770
[TBL] [Abstract][Full Text] [Related]
55. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172
[TBL] [Abstract][Full Text] [Related]
57. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
58. Quality of Care Among Medicare Patients Undergoing Pancreatic Surgery: Safety Grade, Magnet Recognition, and Leapfrog Minimum Volume Standards-Which Quality Benchmark Matters?
Merath K; Mehta R; Tsilimigras DI; Farooq A; Sahara K; Paredes AZ; Wu L; Moro A; Ejaz A; Dillhoff M; Cloyd J; Tsung A; Pawlik TM
J Gastrointest Surg; 2021 Jan; 25(1):269-277. PubMed ID: 32040811
[TBL] [Abstract][Full Text] [Related]
59. Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST).
Patrice GI; Lester-Coll NH; Yu JB; Amdahl J; Delea TE; Patrice SJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):97-106. PubMed ID: 29029885
[TBL] [Abstract][Full Text] [Related]
60. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
Hu X; Hay JW
Lung Cancer; 2018 Sep; 123():166-171. PubMed ID: 30089590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]